Home Three Portfolio Companies of Yifeng Capital Named in GEI China Unicorn and Shenzhen Unicorn & Gazelle Enterprise Reports 2025

Three Portfolio Companies of Yifeng Capital Named in GEI China Unicorn and Shenzhen Unicorn & Gazelle Enterprise Reports 2025

Jul 22, 2025 19:10 CST Updated 19:10
Trinomab

Developer of Natural Fully Human Monoclonal Antibody New Drugs

Genocury

Developer of Novel Therapies in Oncology Genetics and Cell Therapy



q

Click to follow?|Focus on Global Biomedical Investment

图片


On July 18, 2025, the 2025 China (Shenzhen) Unicorn Enterprise Conference, themed "New Quality Driving • Future Leading," was held in Shenzhen.《GEI China Unicorn Enterprise Research Report 2025》《Shenzhen Unicorn Enterprise and Gazelle Enterprise Research Report 2025》Released simultaneously, revealing the current status and trends of unicorn enterprises in China and Shenzhen.

The report shows that, since 2024, the Shenzhen Small and Medium Enterprises Service Bureau has established the Shenzhen Gazelle and Unicorn Enterprise Evaluation Committee, which has selected and built the Shenzhen Gazelle and Unicorn Enterprise Gradient Pool.Shenzhen has 149 potential unicorn companies with a total valuation of approximately 350 billion yuan; 143 seed unicorn companies with a total valuation of about 64.3 billion yuan; and 215 gazelle companies with a total revenue scale of approximately 120 billion yuan in 2023.36% of the companies on the list have received support from the Shenzhen Municipal Government Guidance Fund. State-owned enterprises in Shenzhen, such as Shenzhen Capital Group and Shenzhen High-Tech Investment Group, have collectively invested in over a hundred companies on the list.

"Unicorn companies" refer to those start-up enterprises that possess attributes such as rapid growth, scarcity, and being highly favored by investors, characterized by exponential growth and disruptive innovation.These enterprises have effectively driven the improvement of regional total factor productivity by opening up new scenarios and new tracks, and have become a weathervane for regional economic development and innovation vitality, receiving high attention from the Chinese government. The meeting of the Political Bureau of the CPC Central Committee held on July 30, 2024, pointed out that "it is necessary to provide strong and effective support for the development of gazelle enterprises and unicorn enterprises." The 2025 Government Work Report mentioned "supporting the development of unicorn enterprises and gazelle enterprises, allowing more enterprises to accelerate in new fields and new tracks." Specific enterprise standards are as follows:

(1) Enterprises registered in China with legal person status;

(2) Established for no more than ten years;

(3) Have received private equity investment and are not yet listed;

(4) The post-investment valuation of the latest round of financing exceeds (including) 1 billion US dollars. (The valuation is based on the latest round of financing before December 31, 2024).

In this selection, Efung Capital performed outstandingly, with 3 invested companies selected. Among them, Trinomab was included.2024 GEI List of China's Unicorn CompaniesJiyin Bio SelectedSeed Unicorn Enterprise List, NorthX Life SelectedList of Potential Unicorn Companies



Several portfolio companies of EF Capital selected:

图片

2024GEI China Unicorn Enterprise List

图片

Trinomab

Image
Image

图片

Seed Unicorn Enterprise List

图片

Jiyin Bio

Image

图片

   Potential Unicorn Companies List   

图片

NorthX Biologics

Image

After years of deep cultivation and forward-looking layout in the industry, Efung Capital has successfully nurtured several unicorn companies. Looking ahead, Efung Capital will continue to focus on technological innovation, deepen industry insights, and help more outstanding companies break through growth boundaries!




Recommended Reading


Bokang Vision Cloud Hong Kong Main Board IPO

图片

Shenghe Biotech Hong Kong Main Board IPO

图片

Quanxin Biotech Hong Kong Main Board IPO

图片

Against the Current, Moving Forward with Time

图片

3D Medicines Hong Kong Main Board IPO

图片

Hoyorbio STAR Market IPO

图片

A Decade of Sharpening the Sword, Its Blade Will Surely Gleam Upon Unsheathing

图片

Sci-Tech Innovation Board IPO of YAHONG Pharmaceutical

图片

图片


Looking forward to your

Share

Like

In view